Donor-derived Cell-free DNA Testing in Kidney Transplant Recipients on Reduced Immunosuppression


About this study

The purpose of this study is to determine the incidence of biopsy proven acute rejections detected due to elevated dd-cfDNA independent of change in serum creatinine, to determine incidence of DeNovo Donor specific antibody (DSA) or increase in preexisting DSA’s in presence of elevated dd-cfDNA, and to determine the association of elevated dd-cfDNA with progression of chronic changes in surveillance biopsies.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Decreased immunosuppression for at least 4 weeks.
  • Kidney alone transplant recipients > 1 months and < 24 months after transplant.
  • Medicare insurance or other insurance that would cover the cost of Prospera test.

Exclusion Criteria:

  • Prior organ transplant.
  • Simultaneous 2 or more organ transplants.
  • Patients with contraindication to biopsy.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Pooja Budhiraja, M.B.B.S., M.D.

Open for enrollment

Contact information:

April Howard B.S.N., R.N.

(480) 342-5756

More information


Publications are currently not available

Mayo Clinic Footer